Assessment of Brain Cognitive Impairment in Breast Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
AgeNot listed
SponsorTang-Du Hospital
About this trial
To explore the cognitive impairment caused by chemotherapy and endocrine therapy in premenopausal breast cancer patients and to find biomarkers with early predictive effect on this cognitive impairment by using multimodal integrated PET/MRI technology combined with psychobehavioral technology.
Eligibility criteria
Qualifiers
Patients with primary stage I-II breast cancer.
Premenopausal women (menopausal status determined by National Comprehensive Cancer Network Breast Cancer Guidelines criteria).
No treatment other than surgery has been started (if neoadjuvant chemotherapy is required before surgery, enroll before chemotherapy starts).
Eastern Cooperative Oncology Group score of 0-1 points.
Disqualifiers
Central nervous system (CNS) disease, history of malignancy, chronic loss of consciousness, head trauma, and any disease affecting cognitive function.
Current or former epilepsy, dementia, or learning disabilities.
Past psychiatric history.
Past history of malignancy.
Trial design
Treatments tested in this trial
- PET/MRI, psychobehavioral tests and questionnaires, serum biomarkers and stool sample
Treatment groups
90 Participants
are divided into 3 treatment groupsSponsors and collaborators
Tang-Du Hospital
Lead sponsor
Xi'an Jiaotong University
Collaborator
Source ClinicalTrials.gov